Xbrane Biopharma narrows Q3 loss to SEK -6.6m

Xbrane Biopharma reported Q3 2026 EBITDA of -SEK 6.6 million, improving from -SEK 20.7 million a year earlier. The loss reduction signals improved cost control but provides no revenue or cash-flow detail. This is a routine earnings update for a small-cap biotech, with limited market impact.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works